The protective efficacy of a glycoprotein D subunit vaccine (gD2 SB AS4) was evaluated in a mouse model of human recurrent herpetic stromal keratitis (HSK). When administered before primary infection, gD2 SB AS4 protected mice against corneal pathology, mortality, and latency resulting from ocular viral challenge with herpes simplex virus type 1 (HSV-1) McKrae strain. In addition, gD2 SB AS4 significantly decreased postreactivation corneal disease. A control vaccine, gD2 alum, protected against acute ocular infection only. When administered after primary infection, gD2 SB AS4 vaccination decreased postreactivation ocular shedding but had no other significant effects. Vaccination with gD2 SB AS4 was associated with high anti-gD antibody responses and low delayed-type hypersensitivity responses. These results have identified a prophylactic vaccine, gD2 SB AS4, with activity against acute and recurrent HSK in mice and emphasize the need for vaccine evaluation in both primary and recurrent ocular herpetic disease models.
Herpes simplex virus (HSV) is a leading cause of virus-
Unfortunately, many of the effective adjuvant formulations used in animal studies are associated with adverse side effects induced corneal disease in humans. The pathogenesis of the disease is complex and consists of a primary infection of the that prevent their use in humans. A new vaccine formulation, gD2 SB AS4, shows promise in primate studies as well as in eye, transport of the virus to the sensory ganglia, where acute and latent infection occurs, and periodic reactivation of latent prophylactic and therapeutic models of HSV-2 genital disease [1, 2] . Importantly, this vaccine has been shown to be safe and virus, leading to recurrent corneal disease. Prolonged or repeated inflammatory reactions in the corneal stroma can evenimmunogenic in humans [3, 4] . A murine model of recurrent HSK that mimics the human tually lead to the development of irreversible tissue damage, scarring, neovascularization, and blindness. Thus, recurrent disease has been characterized in our laboratory [5] . In this model, corneas of latently infected mice exposed to ultraviolet herpetic stromal keratitis (HSK) has the greatest potential to impair vision. At the present time, there are no prophylactic B (UV-B) irradiation experience recurrent viral shedding and disease. As in humans, recurrent ocular disease in mice is or therapeutic vaccines that are both safe and effective against recurrent ocular HSV infections in humans.
characterized by the appearance of microdendrites, focal stromal opacification, endotheliitis, and neovascularization [6, 7] . Glycoprotein D (gD), which is present on HSV envelope and infected cell membranes, is one of the prime targets for a By use of this model, we have examined the prophylactic and therapeutic efficacy of gD2 SB AS4 with regard to controlling variety of host immunologic responses and is a particularly good candidate for incorporation into herpesvirus vaccines.
primary and recurrent eye disease produced by HSV-1 infection. 
Materials and Methods

Virus and Cells
All investigations conformed to the ARVO Resolution on the Use of Animals in Research.
The virus used was HSV-1 McKrae strain. A plaque-purified balanced salts (MEM-EBS) containing 5% fetal bovine serum, 100 JID 1997;176 (August)
Mice
Clinical Observation
Female NIH inbred mice were obtained from Harlan Olac (OxEyes were observed through a binocular dissecting microscope ford, UK). The eyes of all mice were examined for corneal opacity by an observer with no knowledge of treatment groups. Stromal before infection and irradiation, and only animals with clear coropacification was rated on a scale of 0-4, where 0 indicates clear neas were used. stroma, 1 indicates mild stromal opacification, 2 indicates moderate opacity with discernible iris features, 3 indicates dense opacity with loss of defined iris detail except pupil margins, and 4 indicates Vaccinations total opacity with no posterior view.
Vaccines contained a truncated form of gD of HSV-2 (gD2). This protein was produced by recombinant DNA technology and Antibody Assays expressed in CHO cells by Genentech (Emeryville, CA) [8] . Production and purification of gD2 were performed at SmithKline ELISA procedure. Serial 3-fold dilutions of mice sera were Beecham Biologicals (Rixensart, Belgium). The protein was puriincubated on ELISA plates coated with purified recombinant gD2 fied to near-homogeneity under nondenaturing conditions from protein (1 mg/mL). The presence of specific antibodies was retransfected CHO culture supernatants. Vaccines consisted of gD2 vealed by addition of anti-mouse immunoglobulin conjugated to combined with aluminum salt (gD2 alum vaccine) or aluminum biotin, followed by streptavidin-biotinylated peroxidase complex. salt with monophosphoryl lipid A, referred to as SB AS4 adjuvant ELISA titers were defined as the reciprocal of the serum dilution formulation (gD2 SB AS4 vaccine). Monophosphoryl lipid A was that produced an absorbance (optical density) measured at 492 nm provided by Ribi ImmunoChem Research (Hamilton, MT). Proequal to 50% of the maximal absorbance value (midpoint titer). phylactic and therapeutic vaccines consisted of 5 and 10 mg of Neutralization procedure. Two-fold dilutions of mice sera gD2, respectively, combined with 100 mg of aluminum salt (alum)
were incubated on 96-well plates with 4000 pfu of HSV-2 strain or 100 mg of aluminum salt plus 25 mg of monophosphoryl lipid HG52 and complement. BHK21 cells were then added to the wells. A (SB AS4). Vaccines were administered subcutaneously in two
The plates were incubated for 3 days, and the appearance of virus sites in a total volume of 0.2 mL. All vaccinations were repeated plaques was monitored by microscopic examination. The neutraliz-3 weeks later.
ing titer was defined as the reciprocal of the serum dilution giving 100% protection against virus-induced cytopathic effects. Infection
Mice were infected as previously described [5] . Briefly, followDelayed-Type Hypersensitivity (DTH) Assays ing corneal scarification, 10 5 or 10 6 pfu of HSV-1 McKrae strain in 5 mL of MEM-EBS was placed onto the eye. Mock-infected In this procedure, 5 1 10 6 pfu (before inactivation) of UVmice received virus-free MEM-EBS in the scarified eye. HSV inactivated HSV-1 McKrae strain in 30 mL of medium was injected model mice consisted of nonvaccinated mice infected as above into the right rear footpad of mice. The left rear footpad was with concurrent administration of 1 mL of pooled human serum injected with 30 mL of virus-free tissue culture medium. Footpad (Chemicon, Temecula, CA; known to have anti-HSV reactivity thickness was determined with a micrometer (Mitutoyo Manufacwith an effective dose for 50% virus neutralization of 1:800).
turing, Tokyo) immediately prior to and 48 h after injection. HSVAdministration of anti-HSV antibodies at the time of ocular infecspecific footpad swelling was determined by the formula (right tion has been previously demonstrated to have a protective effect footpad swelling at 48 hours 0 right footpad swelling before injecduring primary infection, resulting in mice with clear corneas and tion) 0 (left footpad swelling at 48 hours after injection 0 left the ability to undergo recurrent viral shedding (in 70% of latently footpad swelling before injection). Mice used for DTH assays were infected mice) and herpetic ocular disease following UV-B irradiaexcluded from any further studies. tion (250 mJ/cm 2 ) [5] . These antibodies are no longer detectable at the time of UV-B irradiation 5 weeks after primary infection [9] .
Acute Trigeminal Ganglia Virus Titers and Latency
To determine the titer of virus present in trigeminal ganglia 5 UV-B Irradiation days after acute infection with 10 6 pfu of HSV-1 McKrae, ganglia were harvested, disrupted, and plated onto Vero monolayers. ReThe UV-B source used was a TM20 Chromato-Vu transilluminator (UVP, San Gabriel, CA), which emits UV-B at a peak wave sulting virus plaques were quantitated by an observer with no knowledge of treatment groups. For determination of latency, the length of 302 nm. At least 5 weeks after primary infection, the right eyes of latently infected and control mice were exposed to relevant trigeminal ganglion was removed from each mouse 3 weeks after UV-B exposure (8 weeks after primary infection). 250 mJ/cm 2 UV-B light. Before (day 0) and on days 1-7 after UV-B irradiation, the eyes of mice were swabbed with surgical This interval provides adequate time for cessation of active viral replication and return to the latent state. Individual trigeminal ganspears (WeckCel; Xomed-Treace, Jacksonville, FL) saturated with tissue culture medium. The swab material was cultured on Vero glia were minced and incubated on Vero cell monolayers for 3 weeks with three media changes per week. Latency was confirmed cells, as described above, to detect recurrent viral shedding from the cornea.
by the appearance of typical virus plaques.
/ 9d2f$$au39 06-24-97 11:16:14 jinfa UC: J Infect with nonvaccinated mice. Thus, while adjuvant effects were observed for opacity and mortality data at 10 5 pfu, the effect was lost at higher infection levels, and the protective effects Table 2 presents fected and control mice were UV-B-irradiated. Post-UV-B eye data obtained from swabs taken 1, 3, and 5 days after infection.
swabs confirmed recurrent viral shedding. Clinical observation of the eyes of mice was performed on days 0, 3, 7, 14, and 35 relative to infection and on days 0, 7, 14, and 21 relative to UV-B irradiation. Antibody and DTH responses were measured before vaccination and 2 weeks after vaccination, infection, and UV-B exposure for random samples of mice in each treatment group. Therapeutic vaccination. Mice were infected at 4 weeks of age with concurrent administration of protective human serum (HSV model). Five weeks after primary infection, latently infected mice were vaccinated with gD2 SB AS4, SB AS4 alone, or PBS. Mock-infected mice received gD2 SB AS4 or PBS (table 1) . Two weeks after the last vaccination, the inoculated eyes of latently infected and control mice were UV-B-irradiated, and recurrent shedding was confirmed from positive eye swabs. Clinical observation of the eyes of mice was performed on days 0, 7, 14, and 21 after UV-B exposure. 250 mJ/cm 2 UV-B irradiation, with day 0 swabs serving as a control. Although lower reactivation rates relative to the HSV model were noted in all groups at 10 5 and 10 6 pfu, a significant decrease (P Å .05 to .004) was observed only in mice in the gD2 SB AS4, adjuvant, and nonvaccinated groups (figure 4). Reactivation rates of gD2 SB AS4 and nonvaccinated mice were less (P Å .015 and .041) than that of gD2 alum mice at the 10 6 -pfu infection. There was no difference between treatment groups in the number of days virus was shed after reactivation (data not shown). Table 3 presents corneal opacity data for reactivated (virusshedding) mice in each combined 10 5 /10 6 pfu treatment group following UV-B exposure. To control for UV-B effects, corneal opacity of each group was compared with that of mock-infected animals that experienced the same UV-B exposure. Corneal virus-induced pathology, and significantly less than that for gD2 alum (P õ .01), nonvaccinated/alum-vaccinated (P õ .01), and HSV model mice (P õ .05) on days 14 and 21. While both gD2 vaccine groups displayed virus titers that were Corneal opacity in gD2 alum, HSV model, and nonvaccinated/ strikingly lower than that seen in control groups on day 1 (P alum vaccinated groups exceeded that of either or both UV õ .001), the gD2 SB AS4 group demonstrated significantly lower titers than did the gD2 alum group (P Å .0016). In addition, SB AS4 (P õ .001) and HSV model (P Å .004) Table 2 . Effect of prophylactic vaccination on virus titers in tear films and trigeminal ganglia following primary infection.
groups had significantly lower titers than did nonvaccinated animals.
Days after infection
Previous studies indicated that maximal virus titers in trigeminal ganglia occurred at 4 -5 days after acute corneal infecSite, group (n) 1 3 5 tion in nonvaccinated mice [10, 11] significantly lower than in the gD2 alum (60% and 65%), the † P Å .0016, compared with gD2 alum for day 1.
HSV model (71% and 78%), and the control groups (65% - ‡ P õ .001 compared with gD2 SB AS4 and gD2 alum on day 5. § P õ .001 and P Å .0041, compared with SB AS4 and HSV model groups 83%) (P Å .025 to P õ .001). No other differences were found.
for day 1.
Effects on reactivation and postreactivation disease. Reactivax P Å .011, .019, and .027 compared with nonvaccinated, gD2 SB AS4, SB tion was defined as the finding of any HSV-positive eye swab AS4, and gD2 alum on day 3. Ø P õ .001, compared with SB AS4 and nonvaccinated groups.
from latently infected mice during days 1-7 after exposure to / 9d2f$$au39 06-24-97 11:16:14 jinfa UC: J Infect pfu, reactivation rates in gD2 SB AS4, adjuvant, and nonvaccinated groups were less than in HSV model group (P Å .05 to .004). At 10 model, and nonvaccinated/alum-vaccinated groups were equivalent on all days. Previous work in our laboratory has shown that non -virusin controls (P õ .001 to .0012). gD2 SB AS4 vaccination shedding mice may nevertheless harbor reactivated HSV in elicited greater (P Å .0021 for mock, P õ .001 for 10 6 pfu) swab-inaccessible sites, such as deep stromal layers of the anti-gD antibody levels than did gD2 alum vaccination. After cornea. Therefore, latently infected mice that do not shed virus infection, control groups experienced an increase in antibody in their tear film after UV-B irradiation cannot be considered titer, while titers of gD2 vaccinees remained stable, indicating reactivation-negative. The data for ''nonreactivated'' mice are that maximal antibody response was elicited by gD2 vaccinanot presented. determined by ELISA for mice in the study. Mice prophylac- † P õ .05, compared with vaccinated/mock-infected controls.
tically vaccinated with gD vaccines produced high anti-gD2 ‡ P õ .01, compared with gD2 alum-vaccinated and nonvaccinated/alumvaccinated; P õ .05, compared with HSV model.
ELISA titers that were much greater (up to 600-fold) than those / 9d2f$$au39 06-24-97 11:16:14 jinfa UC: J Infect The vaccine tested in our studies consisted of gD2 combined with the adjuvant SB AS4, which contains alum and a nontoxic Antibody derivative of lipid A [4] . gD was selected because it is a target gD2 alum (15) 3202 as these have been reported by other researchers using gD vaccines in murine and rabbit models of primary ocular HSV infection [17 -22] . One study, using HSV-1 (McKrae strain) as the challenge virus, found that prophylactic vaccination with tion. Significantly higher neutralizing antibody levels were also gD1 in complete Freund's adjuvant, a potent and potentially detected in gD2 SB AS4 vaccinees compared with gD2 alum toxic preparation, resulted in acute disease and latency protecvaccinees (gD2 SB AS4 Å 837.83 { 371 vs. gD2 alum Å tion levels in mice that were very similar to those following 459.48 { 197; P Å .025). No differences were seen between vaccination with gD2 SB AS4 [17] . reactivated and nonreactivated mice (data not shown).
Because in humans with ocular HSV infections, permanent corneal scarring and blindness is most often associated with virus recrudescence, the most important findings of our studies induced recurrent HSV shedding compared with gD2 alumtreated and HSV model mice. This effect may be explained, after primary ocular infection with HSV-1 was investigated. Accordingly, 2 weeks after vaccination of latently infected however, by low latency rates in this group (figure 3). Low reactivation rates also occurred in adjuvant and nonvaccinated mice with gD2 SB AS4, SB AS4 alone, or PBS, eyes were UV-B -irradiated and monitored for recurrent viral shedding mouse groups (despite high latency levels), possibly due to corneal nerve damage [23] or protective immune responses and corneal disease. Although there was a tendency for gD2 SB AS4 to decrease the reactivation frequency, this effect was elicited in mice that survive acute infection with the highly neurovirulent McKrae strain of HSV-1. not significant. In addition, gD2 SB AS4 vaccination had no effect on recurrent disease (data not shown). A significant deInterestingly, prophylactic gD2 SB AS4 vaccination was found to decrease HSV-induced recurrent corneal disease (table crease in the average number of days of post -UV-B viral shedding was observed in gD2 SB AS4 vaccinees (P Å .0105
3), while gD2 alum vaccination did not. Thus, in contrast to what was seen in gD2 alum, HSV model, and nonvaccinated/ and .0024) compared with adjuvant-and PBS-treated mice (gD2 SB AS4 Å 1.58 { 0.17 days, SB AS4 Å 2.63 { 0.27 alum groups, stromal opacification in gD2 SB AS4 vaccinees was equivalent to that of both UV-B controls on all days, days, and PBS Å 2.81 { 0.28 days). After therapeutic gD2 SB AS4 vaccination, anti-gD antibody responses were compaindicating a lack of virus-induced pathology. Because transient UV-B -induced corneal opacity may persist in all groups to rable to those arising from prophylactic vaccination with gD2 SB AS4, and DTH responses were of the same magnitude as §7 days after irradiation (Laycock KA, unpublished observa-/ 9d2f$$au39 06-24-97 11:16:14 jinfa UC: J Infect tions), a significant difference in effects between the gD2 SB latent infections and the latent virus load in individual ganglia compared with gD2 alum -vaccinated and HSV model mice. AS4 group and gD2 alum, HSV model, and nonvaccinated/ alum groups occurred only on days 14 and 21.
After UV-B stimulation, lowered latency levels could in turn produce observed decreases in reactivation rate and postreactiWhile only 5 mice in the gD2 SB AS4 group shed virus after UV-B irradiation, several factors suggest that the protecvation disease. Although not demonstrated by our studies, gD2 SB AS4 and tive effect of this vaccine on recurrent HSV-induced corneal opacity is real. First, corneal opacity scores for gD2 SB AS4 monophosphoryl lipid A vaccination has been associated with protective cell-mediated immune responses in other systems vaccinees were equivalent to those of two different mockinfected, UV-B control groups on all days after irradiation.
[ 1 -4, 29] . It is possible that as-yet-uncharacterized cell-mediated immune responses were elicited by vaccination with gD2 Second, like UV-B control groups, in the gD2 SB AS4 group, ú70% of the opacity scores were £2 on days 14 and 21. Third, SB AS4 in our studies and contributed to lower latency rates, reactivation rates, and postreactivation disease in this group. the variance of opacity scores in the gD2 SB AS4 group as measured by standard deviation was small on all days. Fourth, Relevant to this, mice vaccinated with gD and complete Freund's adjuvant before primary ocular HSV infection were corneal opacity in at least 2 separate groups of mice (gD2 alum and HSV model) exhibiting virus-related corneal pathology partially protected from the establishment of latency in association with significant antibody and NK cell activity [20] . was significantly greater than that of gD2 SB AS4 vaccinees on days 14 and 21.
Following therapeutic vaccination with gD2 SB AS4, latently infected mice exhibited high antibody and high DTH This may be the first report of a recombinant gD2 vaccine with efficacy against recurrent HSK when administered before responses (data not shown) but were not protected from recurrent disease. As in other systems, antibody levels in animals primary infection. Nonetheless, in the well-studied guinea pig model of vaginal HSV-2 infection, prophylactic and therapeutic with established latent ocular infections do not correlate with protection from recurrent shedding [30] . Therefore, failure of gD vaccination has been shown to decrease both the severity and frequency of recurrent disease [8, 24 -28] . Also in the therapeutic vaccination with gD2 SB AS4 may be related to the inability of humoral immune responses to modulate recurrent HSV-2 genital disease model, prophylactically administered gD2 SB AS4 provided significant protection against recurrent corneal disease once infection has been established. In addition, high DTH responses present in these animals may have exacergenital disease compared with gD alum [2, 29] .
In this report, we found that systemic vaccination of latently bated corneal disease. Three results from our work suggest that primary ocular infected mice with gD2 SB AS4 decreased the number of days on which virus was shed from the cornea after UV-B irradiation HSV infection models are not sufficient for determining vaccine efficacy against recurrent HSK. First, prophylactic gD2 but had no effect on recurrent HSK. This is in agreement with findings in a rabbit model of spontaneous ocular HSV recuralum vaccination clearly protected against primary ocular infection with HSV-1 but had no effect on recurrent disease. rence, in which therapeutic periocular vaccination of latently infected animals with gB2/gD2 proteins and adjuvant resulted Second, nonvaccinated and adjuvant-vaccinated control mice had high latency levels yet did not reactivate, indicating that in decreased viral shedding and little effect on corneal scarring [30] . In contrast, periocular vaccination with gD1 or gD2 in this latency is not necessarily predictive of true reactivation frequency and postreactivation disease. Third, gD2 SB AS4 vaccisame system decreased the number of recurrent dendritic lesion readings [31] . There may be several explanations as to why nation had positive effects on recurrent disease when given before primary infection but not when given after. Together, therapeutic gD2 SB AS4 vaccination was not clinically effective. Factors shown to influence the outcome of vaccine therapy inthese data emphasize the need for vaccine evaluation in both acute and recurrent models of HSK. clude the immunogen, dose, route of administration, timing of treatment relative to primary infection, adjuvant formulation, and animal model [32] .
